Pan B - Cell Marker : CD 19, in Visit Clinic

CD19 is a transmembrane protein expressed broadly on B‑lineage cells from early precursor (pro‑ and pre‑B) stages through mature B lymphocytes. It is commonly used as a B‑cell marker in immunophenotyping and diagnostics and serves as a therapeutic target (e.g., CAR‑T, monoclonal antibodies). CD19 expression is typically lost when B cells terminally differentiate into plasma cells and is absent on T cells and hematopoietic stem cells.

CD19 positive means a cell expresses the CD19 surface protein, identifying it as part of the B‑cell lineage. It’s used in blood tests and flow cytometry to detect and quantify normal B cells or B‑cell cancers (like certain leukemias and lymphomas). CD19 positivity guides diagnosis, monitoring, and targeted therapies (e.g., anti‑CD19 treatments), but interpretation depends on clinical context.

CD19 is a B‑cell co‑receptor that amplifies B‑cell receptor (BCR) signaling, lowering the activation threshold. It forms complexes with CD21 and CD81, promoting B‑cell development, activation, proliferation, germinal‑center responses and efficient antibody production. CD19 also aids antigen presentation, is expressed through most B‑cell development until plasma‑cell differentiation, and serves as a diagnostic and therapeutic B‑cell marker.

A pan B‑cell marker is a protein expressed broadly across B‑lymphocyte developmental stages that identifies B cells in blood, tissue, and bone marrow. Common examples include CD19, CD20, CD22 and CD79a/PAX5. These markers are used in immunophenotyping (flow cytometry and pathology) to diagnose and classify B‑cell leukemias and lymphomas, guide targeted therapies, and monitor treatment response.

CD19 is a B‑cell marker expressed in most B‑cell malignancies, including B‑cell acute lymphoblastic leukemia (B‑ALL), chronic lymphocytic leukemia (CLL), diffuse large B‑cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma and hairy cell leukemia. It is generally absent on mature plasma cell myeloma. Expression can vary by subtype and disease stage.

CD19 is a B‑cell surface antigen primarily associated with B‑cell malignancies, especially B‑cell acute lymphoblastic leukemia (B‑ALL) and various B‑cell lymphomas such as diffuse large B‑cell lymphoma and chronic lymphocytic leukemia. It’s widely used as a diagnostic marker and therapeutic target (e.g., CD19‑directed CAR T‑cell therapies and monoclonal antibodies) because it’s broadly expressed on malignant B cells.